Author Index

Search or browse for an author across our entire electronic archive

Search results for: O
Results 101 - 110 of 688 shown below

  • O'Toole, D

    A Couvelard, D O'Toole, H Turley, R Leek, A Sauvanet, C Degott, P Ruszniewski, J Belghiti, A L Harris, K Gatter and F Pezzella

    Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression

    advance online publication, 2004-11-23 00:00:00.000;

    doi:10.1038/sj.bjc.6602245

    Abstract | Full article | PDF

  • F Marrache, M P Vullierme, C Roy, Y El Assoued, A Couvelard, D O'Toole, E Mitry, O Hentic, P Hammel, P Lévy, P Ravaud, P Rougier and P Ruszniewski

    Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

    advance online publication, 2006-12-12 00:00:00.000;

    doi:10.1038/sj.bjc.6603526

    Abstract | Full article | PDF

  • O'Toole, S A

    E K A Millar, L R Anderson, C M McNeil, S A O'Toole, M Pinese, P Crea, A L Morey, A V Biankin, S M Henshall, E A Musgrove, R L Sutherland and A J Butt

    BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast

    advance online publication, 2008-12-09 00:00:00.000;

    doi:10.1038/sj.bjc.6604809

    Abstract | Full article | PDF

  • E Y Tan, M Yan, L Campo, C Han, E Takano, H Turley, I Candiloro, F Pezzella, K C Gatter, E K A Millar, S A O'Toole, C M McNeil, P Crea, D Segara, R L Sutherland, A L Harris and S B Fox

    The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy

    doi:10.1038/sj.bjc.6604844

    Abstract | Full article | PDF

  • O'neill, P A

    H E Innes, D Liu, R Barraclough, M P A Davies, P A O'neill, A Platt-Higgins, S de Silva Rudland, D R Sibson and P S Rudland

    Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients

    doi:10.1038/sj.bjc.6603065

    Abstract | Full article | PDF

  • O'quigley, J

    J O'quigley and S Zohar

    Experimental designs for phase I and phase I/II dose-finding studies

    advance online publication, 2006-01-24 00:00:00.000;

    doi:10.1038/sj.bjc.6602969

    Abstract | Full article | PDF

  • O'toole, E A

    J Green, M Ikram, J Vyas, N Patel, C M Proby, L Ghali, I M Leigh, E A O'toole and A Storey

    Overexpression of the Axl tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours

    advance online publication, 2006-04-25 00:00:00.000;

    doi:10.1038/sj.bjc.6603135

    Abstract | Full article | PDF

  • O'toole, L

    D M Greenfield, J Wright, J E Brown, B W Hancock, H A Davies, L O'toole, C Eiser, R E Coleman and R J Ross

    High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening

    advance online publication, 2006-02-07 00:00:00.000;

    doi:10.1038/sj.bjc.6602974

    Abstract | Full article | PDF

  • Oakley, R

    K Gaballah, R Oakley, A Hills, A Ryan and M Partridge

    The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues

    advance online publication, 2009-07-21 00:00:00.000;

    doi:10.1038/sj.bjc.6605092

    Abstract | Full article | PDF

  • Oakley-Girvan, I

    A S Whittemore, R R Balise, P D P Pharoah, R A DiCioccio, I Oakley-Girvan, S J Ramus, M Daly, M B Usinowicz, K Garlinghouse-Jones, B A J Ponder, S Buys, R Senie, I Andrulis, E John, J L Hopper and M S Piver

    Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations

    advance online publication, 2004-11-16 00:00:00.000;

    doi:10.1038/sj.bjc.6602239

    Abstract | Full article | PDF

  • Oates, J

    N C Tebbutt, A R Norman, D Cunningham, M Allen, I Chau, J Oates and M Hill

    Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil

    doi:10.1038/sj.bjc.6600917

    Abstract | Full article | PDF

  • A Saini, A R Norman, D Cunningham, I Chau, M Hill, D Tait, T Hickish, T Iveson, F Lofts, D Jodrell, P J Ross and J Oates

    Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

    doi:10.1038/sj.bjc.6600995

    Abstract | Full article | PDF

  • S Rao, D Cunningham, T Price, M E Hill, P J Ross, N Tebbutt, A R Norman, J Oates and P Shellito

    Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

    advance online publication, 2004-07-20 00:00:00.000;

    doi:10.1038/sj.bjc.6602039

    Abstract | Full article | PDF

  • K Sumpter, C Harper-Wynne, D Cunningham, S Rao, N Tebbutt, A R Norman, C Ward, T Iveson, M Nicolson, T Hickish, M Hill and J Oates

    Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

    doi:10.1038/sj.bjc.6602572

    Abstract | Full article | PDF

  • S Rao, D Cunningham, R E Hawkins, M E Hill, D Smith, F Daniel, P J Ross, J Oates and A R Norman

    Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

    advance online publication, 2005-04-26 00:00:00.000;

    doi:10.1038/sj.bjc.6602576

    Abstract | Full article | PDF

  • G Chong, J L B Dickson, D Cunningham, A R Norman, S Rao, M E Hill, T J Price, J Oates and N Tebbutt

    Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

    advance online publication, 2005-08-09 00:00:00.000;

    doi:10.1038/sj.bjc.6602733

    Abstract | Full article | PDF

  • N R Maisey, A R Norman, A Hill, A Massey, J Oates and D Cunningham

    CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

    advance online publication, 2005-09-20 00:00:00.000;

    doi:10.1038/sj.bjc.6602760

    Abstract | Full article | PDF

  • V Formica, A Wotherspoon, D Cunningham, A R Norman, B Sirohi, J Oates and G Chong

    The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

    advance online publication, 2007-04-03 00:00:00.000;

    doi:10.1038/sj.bjc.6603699

    Abstract | Full article | PDF

  • S Rao, N Starling, D Cunningham, M Benson, A Wotherspoon, C Lüpfert, R Kurek, J Oates, J Baselga and A Hill

    Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

    advance online publication, 2008-09-02 00:00:00.000;

    doi:10.1038/sj.bjc.6604622

    Abstract | Full article | PDF

  • N Starling, A Okines, D Cunningham, W Allum, A Wotherspoon, M Benson, J Thompson, J Thomas, G Brown, A Riddell, F Stavridi, S Ashley, J Oates and I Chau

    A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma

    advance online publication, 2009-05-12 00:00:00.000;

    doi:10.1038/sj.bjc.6605070

    Abstract | Full article | PDF

  • L Assersohn, A Norman, D Cunningham, T Benepal, P J Ross and J Oates

    Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma

    doi:10.1038/sj.bjc.6690287

    Abstract | Full article | PDF

  • J S Waters, A Norman, D Cunningham, J H Scarffe, A Webb, P Harper, J K Joffe, M Mackean, J Mansi, M Leahy, A Hill, J Oates, S Rao, M Nicolson and T Hickish

    Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

    doi:10.1038/sj.bjc.6690350

    Abstract | Full article | PDF

  • H J N Andreyev, A R Norman, D Cunningham, J Oates, B R Dix, B J Iacopetta, J Young, T Walsh, R Ward, N Hawkins, M Beranek, P Jandik, R Benamouzig, E Jullian, P Laurent-Puig, S Olschwang, O Muller, I Hoffmann, H M Rabes, C Zietz, C Troungos, C Valavanis, S T Yuen, J W C Ho, C T Croke, D P O'Donoghue, W Giaretti, A Rapallo, A Russo, V Bazan, M Tanaka, K Omura, T Azuma, T Ohkusa, T Fujimori, Y Ono, M Pauly, C Faber, R Glaesener, A F P M de Goeij, J W Arends, S N Andersen, T Lövig, J Breivik, G Gaudernack, O P F Clausen, P De Angelis, G I Meling, T O Rognum, R Smith, H-S Goh, A Font, R Rosell, X F Sun, H Zhang, J Benhattar, L Losi, J Q Lee, S T Wang, P A Clarke, S Bell, P Quirke, V J Bubb, J Piris, N R Cruickshank, D Morton, J C Fox, F Al-Mulla, N Lees, C N Hall, D Snary, K Wilkinson, D Dillon, J Costa, V E Pricolo, S D Finkelstein, J S Thebo, A J Senagore, S A Halter, S Wadler, S Malik, K Krtolica and N Urosevic

    Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

    doi:10.1054/bjoc.2001.1964

    Abstract | Full article | PDF

  • Oates, J R

    I Chau, A R Norman, D Cunningham, J S Waters, C Topham, G Middleton, M Hill, P J Ross, R Katopodis, G Stewart and J R Oates

    Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

    advance online publication, 2004-09-14 00:00:00.000;

    doi:10.1038/sj.bjc.6602169

    Abstract | Full article | PDF